Showing results (1-10 of 176) with videos related to
Sort By:
Pageof 18
Expert Opinion on Investigational Drugs|January 8, 2011
Mipomersen, an antisense apolipoprotein B synthesis inhibitorDamon A Bell, Amanda J Hooper, John R BurnettExpert Opinion on Pharmacotherapy|September 21, 2024
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemiaAmanda J Hooper, Damon A Bell, John R BurnettExpert Opinion on Pharmacotherapy|August 8, 2025
Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemiaAmanda J Hooper, Damon A Bell, John R BurnettCurrent Atherosclerosis Reports|May 21, 2018
The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and CaveatsAmanda J Hooper, John R Burnett, Damon A Bell, et al.Vascular Health and Risk Management|December 11, 2012
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemiaDamon A Bell, Amanda J Hooper, Gerald F Watts, et al.Expert Opinion on Pharmacotherapy|April 24, 2025
Sepiapterin for the treatment of phenylketonuriaRobin A Williams, Damon A Bell, Amanda J Hooper, et al.Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and childrenMichael M Page, Damon A Bell, Amanda J Hooper, et al.Pathology|January 2, 2019
Update on the diagnosis, treatment and management of rare genetic lipid disordersDavid M Ng, John R Burnett, Damon A Bell, et al.Pathology|January 1, 2015
Plasma cholesterol in adults with phenylketonuriaRobin A Williams, Amanda J Hooper, Damon A Bell, et al.Clinical Chemistry|July 17, 2019
Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?Dick C Chan, Jing Pang, Amanda J Hooper, et al.Pageof 18